Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: A randomized prospective study using intravascular ultrasound

International Journal of Cardiology

Volumn 138, Issue 2, 2010, Pages 157-165

  Nakayama, Takashi ^a   Komiyama, Nobuyuki ^b   Yokoyama, Masaki ^a   Namikawa, Susumu ^a   Kuroda, Nakabumi ^a   Kobayashi, Yoshio ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Coronary plaque stabilization; Intravascular imaging; PPAR agonist; Vascular pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTRAVASCULAR ULTRASOUND; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PPAR GAMMA; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 73749087583     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.08.031     Document Type: Article

References (57)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
2. Malmberg K., and Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 9 (1988) 259-264
3. Fava S., Azzopardi J., and Agius-Muscat H. Outcome of unstable angina in patients with diabetes mellitus. Diabet Med 14 (1997) 209-213
4. Shinozaki K., Suzuki M., Ikebuchi M., Hara Y., and Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 19 (1996) 1-7
5. Takagi T., Yoshida K., Akasaka T., et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 36 (2000) 731-738
6. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
7. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. The CARE Investigators. Circulation 98 (1998) 2513-2519
8. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 364 (2004) 685-696
9. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
11. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
12. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
13. Kotchen T.A., Zhang H.Y., Reddy S., and Hoffmann R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270 (1996) 660-666
14. Parukar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., and Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
15. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
16. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
17. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146 (2003) 366
18. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
19. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. A randomized trial. JAMA 296 (2006) 2572-2581
20. Langenfeld M.R., Forst T., Hohberg, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
22. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents developed in collaboration with the European Society of Cardiology endorsed by the Society of Cardiac Angiography and Interventions. Eur J Echocardiogr 4 (2001) 299-313
23. Yokoyama M., Komiyama N., Courtney B.K., et al. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J 150 (2005) 287.e1-287.e7
24. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
25. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
26. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemia Syndromes) Registry. Circulation 102 (2000) 1014-1019
27. Fujishima M., Kiyohara Y., Kato I., et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 45 Suppl 3 (1996) S14-S16
28. Wagenknecht L.E., D'Agostino Jr. R.B., Haffner S.M., Savage P.J., and Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: The Insulin Resistance Atherosclerosis Study. Diabetes Care 21 (1998) 1812-1818
29. Festa A., D'Agostino Jr. R.B., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
30. Fagan T.C., and Deedwania P.C. The cardiovascular dysmetabolic syndrome. Am J Med 105 (1998) 77S-82S
31. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
32. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 (1998) 1097-1103
33. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPAR-γ: differentiation-dependent peroxisome proliferators-activated receptor gamma (PPAR-γ) expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro. Am J Pathol 153 (1998) 17-23
34. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
35. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
36. Hedblad B., Zambanini A., Nilsson P., Janzon L., and Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 261 (2007) 293-305
37. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
38. Deeg M.A., Buse J.B., Goldberg R.B., et al. GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30 (2007) 2458-2464
39. Aizawa Y., Kawabe J., Hasebe N., Takehara N., and Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104 (2001) 455-460
40. Gaillard V., Casellas D., Seguin-Devaux C., et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 46 (2005) 372-379
41. Sourij H., Zweiker R., Wascher T.C., et al. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29 (2006) 1039-1045
42. Nissen S.E. Rationale for a postintervention continuum of care: insights from intravascular ultrasound. Am J Cardiol 86 (2000) 12H-17H
43. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
44. Jensen L.O., Thayssen P., Pederson K.E., and Haghfelt T. Regression of coronary atherosclerosis by simvastatin. A serial intravascular ultrasound study. Circulation 110 (2004) 265-270
45. Okazaki S., Yokoyama T., Miyauchi K., et al. Volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 110 (2004) 1061-1068
46. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 291 (2004) 1071-1080
47. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 295 (2006) 1556-1565
48. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
49. Nissen S.E., Nicholls S.J., Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. JAMA 299 (2008) 1547-1560
50. Sipahai I., Tuzcu E.M., Schoenhagen P., et al. Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis 189 (2006) 229-235
51. Schoenhagen P., Tuzcu E.M., Apperson-Hansen C., et al. Determinants of arterial wall remodeling during lipid-lowering therapy. Serial intravascular ultrasound observations from the REVERSAL trial. Circulation 113 (2006) 2826-2834
52. Klein L.W. Atherosclerosis regression, vascular remodeling, and plaque stabilization. J Am Coll Cardiol 49 (2007) 271-273
53. Glacov S., Weisenberg B.A., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
54. Erdmann E., Dormandy J., Wilcox R., Massi-Benedetti M., and Charbonnel B. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag 3 (2007) 355-370
55. Tearney G.J., Yabushita H., Houser S.L., et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 107 (2003) 113-119
56. Stefanadis C., Diamantopoulos L., Vlachopoulos C., et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo. A new method of detection by application of a special thermography catheter. Circulation 99 (1999) 1965-1971
57. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150